EUCTR2006-002833-19-IT进行中（未招募）不适用
A randomised, multi-centre, open-label study to evaluate the efficacy of VANIQA with laser treatment versus laser treatment alone in female subjects with excessive facial hair facial hirsutism - ND
Shire Pharmaceutical Ltd0 个研究点目标入组 200 人开始时间: 2006年11月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Female subjects aged 18 years and over Satisfactory medical assessment with no clinically significant and relevant abnormalities of medical history or physical examination Clinical diagnosis of facial hirsutism/excessive facial hair Subjects with Fitzpatrick skin type I-IV For effective photoepilation skin/hair contrast must be adequate hair in target areas to be predominantly brown or black in colour
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of electrolysis or epilation plucking, waxing, Epilady, sugaring, etc. to remove hair within six weeks before start of study or regular use of any other medication that could affect improve or worsen the condition being studied, or could affect the action, absorption or disposition of the investigational product or clinical assessments Use of laser to remove hair within six months before start of study Facial conditions such as severe inflammatory acne Use of systemic antiandrogens, growth hormone, insulin-sensitising agents, spironolactone, immunostimulants, immunosuppressants, dehydroepiandrosterone DHEA , minoxidil, flutamide or other medications considered to have an effect on hair growth within 6 months of the study Change of oral contraceptive within 6 months prior to screening Use of concomitant therapy with any medication considered to exacerbate or be a useful treatment of hirsutism including ketoconazole. Cyproterone acetate use is allowed up to a maximum dose of 2mg per day. Presence of significant scarring, haemangioma, melanocytic naevi or any other abnormalities in the Trichoscan reference area Hepatic/renal impairment History of skin malignancy A history of androgen secreting tumour A known severe hyperandrogenaemia or hormonal imbalance requiring or likely to require systemic treatment during the course of the study Female subjects who are pregnant or lactating, including females with a positive pregnancy test at screening Subjects must not have used another investigational product or taken part in a clinical trial within the last 30 days prior to randomisation Known or suspected intolerance or hypersensitivity to the investigational products or any stated ingredients Systemic or topical treatment with phenytoin, retinoids, cyclosporin or corticosteroids; Current or recurrent disease that could affect the site of application, the action, absorption or disposition of the investigational product or clinical assessments Patients will not be permitted to use plucking as a method to remove facial hair for the duration of the study
研究者
相似试验
进行中（未招募）
1 期
A randomised, multi-centre, open-label study to evaluate the efficacy of VANIQA with laser treatment versus laser treatment alone in female subjects with excessive facial hair (facial hirsutism)Excessive facial hair in females (Facial hirsutism)MedDRA version: 8.1Level: LLTClassification code 10020112Term: HirsutismEUCTR2006-002833-19-ATShire Pharmaceutical Development200
进行中（未招募）
不适用
An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine (REPEVAX) administered concomitantly versus non-concomitantly with an influenza vaccine (VAXIGRIP) to subjects of 60 years of age and olderEUCTR2010-021068-13-DESanofi Pasteur MSD S.N.C.954
进行中（未招募）
1 期
An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine (REPEVAX) administered concomitantly versus non-concomitantly with an influenza vaccine (VAXIGRIP) to subjects of 60 years of age and olderEUCTR2010-021068-13-FRSanofi Pasteur MSD S.N.C.
进行中（未招募）
不适用
A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator´s choice) in adult patients with gastrointestinal stromal tumors resistant to both imatinib and sunitinibGastrointestinal stromal tumors (GIST)EUCTR2006-002267-11-DEovartis Pharma Services AG237
已完成
3 期
A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator's choice) in adult patients with gastrointestinal stromal tumors resistant to both imatinib and sunitinib.10017991GISTNL-OMON30672ovartis10